Nara Biosciences

Nara Biosciences is a preclinical-stage biotechnology company dedicated to developing innovative therapies for neurological disorders, with a primary focus on ischemic stroke. Spun out from Washington University in St. Louis, the company leverages the research of Dr. Jin-Moo Lee to address the challenge of delivering therapeutic agents across the blood-brain barrier (BBB). Their proprietary platform utilizes receptor-mediated transcytosis, specifically targeting the LRP1 receptor, to transport neuroprotective drugs into the central nervous system. By improving drug delivery efficiency, Nara Biosciences aims to reduce brain damage and improve functional outcomes for patients following acute neurovascular events. The company is currently advancing its lead programs through preclinical validation with support from regional venture partners like BioGenerator.